Year : 2020  |  Volume : 5  |  Issue : 4  |  Page : 171-174

Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era

Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China

Correspondence Address:
Qing Yang
Department of Cardiology, Tianjin Medical University General Hospital, 154, Anshan Road, Heping District, Tianjin 300052
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2470-7511.305417

Get Permissions

Emerging evidence indicates that thromboembolic complications are a key determinant of inhospital mortality of patients with COVID-19. Prophylactic anticoagulation therapy is an important component of inhospital management of patients with COVID-19. Considering that millions of patients worldwide are prescribed oral anticoagulation therapy, herein, we summarize the pros and cons of non-Vitamin K antagonist oral anticoagulants (NOACs) and warfarin, in terms of pharmacodynamics, and therapeutic efficacy and adverse effect monitoring in the context of the global pandemic of COVID-19. Despite a lack of evidence from high-quality randomized trials, an NOAC, rather than warfarin, would be a scientifically reasonable treatment option for patients with COVID-19 in the outpatient setting.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded120    
    Comments [Add]    

Recommend this journal